Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BOPA 2017 | Practical intricacies surrounding biosimilar adoption

Simon Cheesman • 6 Oct 2017
BOPA 2017
General Antibodies Rituximab

There are many intricacies surrounding the introduction of biosimilars. Here, Simon Cheesman, BPharm, MRPharmS from University College London Hospital (UCLH), London, UK discusses some of these issues, including whether patients need to be re-consented for treatment, the attitudes of health care professionals towards the adoption of biosimilars and the essential role pharmacists will serve. This interview was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK. This content has been supported by Napp Pharmaceuticals through an unrestricted educational grant to Magdalen Medical Publishing. The company has had no influence on the production of the content.

More from Simon Cheesman

2:14
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
Simon Cheesman • 12 Oct 2018
0:54
The switch to biosimilar rituximab at UCH: 12 months on
Simon Cheesman • 12 Oct 2018
1:12
An audit of infusion-related reactions with biosimilar rituximab in London
Simon Cheesman • 6 Oct 2017
The introduction of biosimilar rituximab: a case study from the pharmacist's perspective
Simon Cheesman • 7 Oct 2017

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals